Phase IV Study With a 36-week Extension Period to Evaluate the Efficacy and Safety of Dapagliflozin Therapy When Added to the Therapy of Japanese Patients With Type 2 Diabetes With Inadequate Glycemic Control on Insulin.

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 266 participants.

Also called NCT02157298

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 266 participants (enrolled count) (from the registry)
Sponsor
  • AstraZeneca Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02157298
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Japan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02157298. Randomized; quadruple masking; primary purpose treatment. Start 2014-06 (registry gives no type); primary completion 2015-02 (actual). Results posted on 2016-03-17.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Phase IV Study With a 36-week Extension Period to Evaluate the Efficacy and Safety of Dapagliflozin Therapy When Added to the Therapy of Japanese Patients With Type 2 Diabetes With Inadequate Glycemic Control on Insulin.
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Dapagliflozin 5 mg
Intervention (Drug)
Placebo tablet
Lead sponsor
AstraZeneca (class: industry)

Record details

Record id
cardio:ct-nct02157298
Content hash
31421cbcb4c3711eebfa8b3ab5e84a5dcc8630379c19c886e61a2dbd4588512a